Learning Objectives:

1. Review the rationale, data and recommendations for germline pharmacogenomic testing in oncology patients
2. Discuss methods for ongoing and planned analysis to assess the potential impact of pharmacogenomic testing in oncology at the University of Chicago
3. Propose a design for a randomized controlled clinical trial examining the impact of pharmacogenomic testing in oncology patients at the University of Chicago

and

1. Review current mechanisms of immunotherapy
2. Discuss additional opportunities to enhance the anti-tumor immune response

                               3. Discuss new candidate immuno-regulatory molecules